Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NovaDel Pharma Inc.

www.novadel.com

Latest From NovaDel Pharma Inc.

Don't Sleep On DTC Compliance: FDA Dings Zolpimist Superiority Claim Vs Ambien

Warning letter objects to webpage and meeting exhibit material for excluding any risk information and suggesting mist formulation is superior to oral zolpidem products.

BioPharmaceutical Regulation

US Capitol Capsule: NIH collaboration sheds light on sleep deprivation's toll

Research has shown that going without 7-8 hours of sleep each night takes a great toll on the human body, resulting in an increased risk for obesity, diabetes, cardiovascular disease, mental illness, cancer growth, Alzheimer's disease and other health problems, according to the National Institutes of Health (NIH).

Metabolic Disorders Gynecology & Urology

Deal Notes: GlycoMimetics/Pfizer, Pharmacyclics/Servier, TG Therapeutics/Rhizen, Takeda/BioMotiv, Amherst/NovaDel

Pfizer delays Phase III study with GlycoMimetics drug; Pharmacyclics, Servier end agreement; TG Therapeutics licenses drug from Rhizen; Takeda invests $25m in BioMotiv; and Amherst buys NovaDel's ZolpiMist.

Orthopedics Inflammation

FDA cuts starting dose for Sunovion's Lunesta in half

Just like it did last year with Sanofi's Ambien (zolpidem) and other zolpidem-containing products, the FDA on 15 May told Sunovion Pharmaceuticals to lower the recommended starting dose of its sleep aid drug Lunesta (eszopiclone) – halving the dose from 2mg to 1mg – citing data showing some patients may have impaired driving the morning after use, even if they feel fully awake.

Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Flemington Pharmaceutical Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NovaDel Pharma Inc.
  • Senior Management
  • Steven B Ratoff, Chmn., Pres. & CEO, & Interim CFO
  • Contact Info
  • NovaDel Pharma Inc.
    Phone: (908) 203-4640
    1200 Rte. 22 E., Ste. 2000
    Bridgewater, NJ 08807
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register